Pre-school Age Participation in Mass Drug Administration: Analysing the Impact on Community-wide Schistosomiasis Control
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Schistosome infection in childhood is common and can lead to morbidity. A formulation of praziquantel to treat pre-school-aged children (PSAC) has been developed recently. This paper assesses what impact including PSAC in mass drug administration (MDA) may have on transmission and morbidity at a community-wide level.
Methods
We utilise a model of schistosome transmission to simulate the probability of a community reaching elimination as a public health problem (EPHP) and the reduction in morbidity of children resulting from infections until the age of five, measured by a ‘Worm Years’ metric as a score of morbidity.
Results
Including PSAC in MDA will almost always lead to a reduction in morbidity. However, it does not necessarily result in a substantial increase in the probability of EPHP. The proportion of schistosome infections in each age group is a key factor in determining the effectiveness of MDA programmes which prioritise different age groups for treatment.
Conclusions
Policy makers should be aware that including PSAC in MDA may not help to reach the WHO target of EPHP. However, a reduction in the average summed worm infection burden at the age children typically start attending school is highly desirable in increasing the long-term benefit of MDA in early childhood.
